サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1592655

アジア太平洋のボツリヌス毒素市場：2031年までの予測 - 地域別分析 - 製品別、用途別、エンドユーザー別

Asia Pacific Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)

出版日
ページ情報
英文 81 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
アジア太平洋のボツリヌス毒素市場：2031年までの予測 - 地域別分析 - 製品別、用途別、エンドユーザー別
出版日: 2024年09月16日
発行: The Insight Partners
ページ情報: 英文 81 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋のボツリヌス毒素市場は、2023年に9億2,529万米ドルとなり、2031年までには27億4,318万米ドルに達すると予測され、2023年から2031年にかけて14.6%のCAGRを記録すると推定されています。

顔面美容のためのボツリヌス毒素使用の増加がアジア太平洋のボツリヌス毒素市場を押し上げる

美容整形とボツリヌス毒素注射は、最も人気のある非侵襲的若返り術の1つです。ISAPSによると、2020年、ボツリヌス毒素治療は、世界中で行われた非侵襲的な美容施術の主要なものでした。さらに、A型ボツリヌス毒素（BoNTA）ベースの美容顔面治療は、顔の上部と下部の美観を改善するために行われています。過去10年間で、顔の若返り術は、様々な種類の伝統的な手術よりも大きな人気を得ています。ISAPSによると、2020年には世界で730万件のボツリヌス毒素施術が行われました。このように、あらゆる年齢層の男女を問わず、顔の美容処置におけるボツリヌス毒素の採用が急増しており、ボツリヌス毒素市場の成長を牽引しています。

アジア太平洋のボツリヌス毒素市場概要

アジア太平洋のボツリヌス毒素市場は、中国、インド、日本、韓国、オーストラリア、その他アジア太平洋に区分されます。頭痛や片頭痛に悩む人の数は年々増加しており、ボツリヌス毒素は慢性片頭痛患者の頭痛の頻度や重症度を減らすのに効果的であることが証明されています。さらに、美的魅力を向上させるための肌の若返りなどの美容整形に対する意識の高まりと医療費の増加が、この地域におけるボツリヌス毒素市場の成長を後押ししています。日本の美容産業は過去に大きな成長を遂げました。この業界は発達しており、幅広い美容製品を利用することができます。業界は高度に規制されているため、美容施術を行うのは医療免許を持つ医師のみです。同国の市場は主に、容姿の変化や維持に投資することを望む消費者の増加によって牽引されています。ISAPSによると、2021年には全国で45万8,749件のボツリヌス毒素施術が行われました。同国は、世界で非外科的美容施術を行っている全ての国の中で3位にランクされ、世界で行われた施術全体の6.3％を占めています。

さまざまな国際企業が、筋痙縮を治療する製品の承認を取得しています。そのため、日本企業は市場での地位を確保するために戦略的イニシアティブをとってきました。2021年6月、Teijin Pharma Limitedとerz GroupのMerz Therapeuticsは共同で、Teijin Pharmaがゼオミン（インコボツリヌムトキシンA）の販売承認を厚生労働省から追加取得したと発表しました。下肢痙縮の治療には、ゼオミンを50、100、200単位で筋肉内注射します。この戦略的な動きは、日本におけるゼオミンの痙縮治療適応の上市に成功し、両社に利益をもたらしました。このような事例により、さまざまな病態のボツリヌス毒素を開発する企業が日本市場に参入することが期待されます。

アジア太平洋のボツリヌス毒素市場の収益と2031年までの予測（金額）

アジア太平洋のボツリヌス毒素市場のセグメンテーション

アジア太平洋のボツリヌス毒素市場は、製品、用途、エンドユーザー、国に分類されます。

製品別では、アジア太平洋のボツリヌス毒素市場はボツリヌス毒素Aとボツリヌス毒素Bに二分されます。2023年のアジア太平洋のボツリヌス毒素市場シェアでは、ボツリヌス毒素Aセグメントが大きなシェアを占めています。

用途別では、アジア太平洋のボツリヌス毒素市場は医療と美容に二分されます。2023年のアジア太平洋のボツリヌス毒素市場では、医療セグメントがより大きなシェアを占めています。さらに、医療セグメントは慢性片頭痛、筋痙攣、過反応性膀胱、多汗症、その他に細分化されます。さらに、美容セグメントは、しかめ面ライン／グラベラー、額ライン、カラスの足跡、四角い顎／咬筋、その他に細分化されます。

エンドユーザー別では、アジア太平洋のボツリヌス毒素市場は専門・皮膚科クリニック、病院・クリニック、その他に分けられます。2023年のアジア太平洋のボツリヌス毒素市場では、専門・皮膚科クリニックセグメントが最大のシェアを占めています。

国別では、アジア太平洋のボツリヌス毒素市場は、日本、中国、インド、韓国、オーストラリア、その他アジア太平洋に区分されます。2023年のアジア太平洋のボツリヌス毒素市場シェアは日本が独占しました。

Merz Pharma GmbH &Co KGaA、AbbVie Inc、Ipsen SA、Evolus Inc、Medytox Inc、Galderma SA、Hugel Inc、Lanzhou Institute of Biological Products Co Ltdは、アジア太平洋のボツリヌス毒素市場で事業を展開する主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋のボツリヌス毒素市場：主要市場力学

  • 市場促進要因
    • 非侵襲的美容施術の人気上昇
    • 顔面美容のためのボツリヌス毒素使用の増加
  • 市場抑制要因
    • ボツリヌス毒素の副作用
  • 市場機会
    • 新興国における美容施術の採用増加
  • 今後の動向
    • 治療用途の拡大
  • 促進要因と抑制要因の影響

第5章 ボツリヌス毒素市場：アジア太平洋の分析

  • ボツリヌス毒素市場の収益、2021年～2031年

第6章 アジア太平洋のボツリヌス毒素市場分析：製品別

  • ボツリヌス毒素A
  • ボツリヌス毒素B

第7章 アジア太平洋のボツリヌス毒素市場の分析：用途別

  • 医療
  • 美容

第8章 アジア太平洋のボツリヌス毒素市場の分析：エンドユーザー別

  • 専門クリニック・皮膚科クリニック
  • 病院・クリニック
  • その他

第9章 アジア太平洋のボツリヌス毒素市場：国別分析

  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • その他アジア太平洋

第10章 企業プロファイル

  • Merz Pharma GmbH & Co KGaA
  • AbbVie Inc
  • Ipsen SA
  • Evolus Inc
  • Medytox Inc
  • Galderma SA
  • Hugel Inc
  • Lanzhou Institute of Biological Products Co Ltd

第11章 付録

図表

List Of Tables

  • Table 1. Botulinum Toxin Market Segmentation
  • Table 2. Asia Pacific Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 3. Asia Pacific Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 4. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 5. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 6. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 7. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 8. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 9. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 10. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 11. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 12. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 13. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 15. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 16. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 17. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 18. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 19. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 20. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 21. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 22. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 23. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 24. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 25. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 26. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 27. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 28. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 29. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 30. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 31. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Medical
  • Table 32. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by Aesthetic
  • Table 33. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 34. Glossary of Terms

List Of Figures

  • Figure 1. Botulinum Toxin Market Segmentation, by Country
  • Figure 2. Botulinum Toxin Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021-2031
  • Figure 5. Botulinum Toxin Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Botulinum Toxin Market Share (%) - by Application (2023 and 2031)
  • Figure 9. Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Botulinum Toxin Market Share (%) - by End User (2023 and 2031)
  • Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Asia Pacific: Botulinum Toxin Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 16. Asia Pacific: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 17. Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
目次
Product Code: TIPRE00028639

The Asia Pacific botulinum toxin market was valued at US$ 925.29 million in 2023 and is expected to reach US$ 2,743.18 million by 2031; it is estimated to register a CAGR of 14.6% from 2023 to 2031.

Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics Boosts Asia Pacific Botulinum Toxin Market

Cosmetic surgery and injectable botulinum toxin are among the most popular noninvasive rejuvenation procedures. According to the ISAPS, in 2020, the botulinum toxin treatment was the leading noninvasive cosmetic procedure performed worldwide. Moreover, the use of botulinum toxin type A-based (BoNTA) cosmetic facial treatments are performed to improve the aesthetics of the upper and lower face. In the last decade, a facial rejuvenation procedure has gained significant popularity over different types of traditional surgeries. According to the ISAPS, ~7.3 million botulinum toxin procedures were performed globally in 2020. Thus, the surge in the adoption of botulinum toxin in facial aesthetic procedures for both men and women from all age groups is driving the botulinum toxin market growth.

Asia Pacific Botulinum Toxin Market Overview

The Asia Pacific botulinum toxin market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. The number of people suffering from headache or migraine has been rising every year, and botulinum toxin has been proven effective in reducing the frequency and severity of headaches in patients with chronic migraine. Moreover, the rising awareness of cosmetic procedures such as skin rejuvenation to improve aesthetic appeal and an increase in healthcare expenditure help to boost the growth of the botulinum toxin market in the region. The aesthetic industry in Japan has witnessed massive growth in the past. The industry is well-developed and has access to a wide range of aesthetic products. The industry is highly regulated, and hence, only licensed medical doctors perform aesthetic procedures. The market in the country is mainly driven by the increasing number of consumers willing to invest in altering and maintaining their looks. According to the ISAPS, in 2021, 458,749 botulinum toxin procedures were performed across the country. The country ranks 3rd among all the countries performing nonsurgical aesthetic procedures in the world, with share of 6.3% of the total procedures performed in the world.

Various international companies have obtained approvals for their products that treat muscle spasticity. Thus, Japanese firms have taken strategic initiatives to secure their positions in the market. In June 2021, Teijin Pharma Limited and Merz Therapeutics, a business of the Merz Group, together announced that Teijin Pharma had been granted additional approval by Japan's Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA). To treat lower limb spasticity, Xeomin would be used in the form of intramuscular injection in 50, 100, or 200 units. This strategic move has benefited both companies for the successful launch of Xeomin to treat spasticity indication in Japan. Thus, such instances are expected to encourage more players to develop botulinum toxin for different medical conditions to enter the Japanese market.

Asia Pacific Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Botulinum Toxin Market Segmentation

The Asia Pacific botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the Asia Pacific botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of Asia Pacific botulinum toxin market share in 2023.

In terms of application, the Asia Pacific botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of Asia Pacific botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the Asia Pacific botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of Asia Pacific botulinum toxin market in 2023.

Based on country, the Asia Pacific botulinum toxin market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Japan dominated the Asia Pacific botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the Asia Pacific botulinum toxin market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Botulinum Toxin Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
    • 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
  • 4.2 Market Restraints
    • 4.2.1 Side Effects of Botulinum Toxin
  • 4.3 Market Opportunities
    • 4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
  • 4.4 Future Trends
    • 4.4.1 Expanding Therapeutic Applications
  • 4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - Asia Pacific Analysis

  • 5.1 Overview
  • 5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Botulinum Toxin Market Analysis - by Product

  • 6.1 Overview
  • 6.2 Botulinum Toxin A
    • 6.2.1 Overview
    • 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Botulinum Toxin B
    • 6.3.1 Overview
    • 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Botulinum Toxin Market Analysis - by Application

  • 7.1 Overview
  • 7.2 Medical
    • 7.2.1 Overview
    • 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.2.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Medical
  • 7.3 Aesthetic
    • 7.3.1 Overview
    • 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.3.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Aesthetic

8. Asia Pacific Botulinum Toxin Market Analysis - by End User

  • 8.1 Overview
  • 8.2 Specialty and Dermatology Clinics
    • 8.2.1 Overview
    • 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Hospitals and Clinics
    • 8.3.1 Overview
    • 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Botulinum Toxin Market - Country Analysis

  • 9.1 Asia Pacific: Botulinum Toxin Market
    • 9.1.1 Asia Pacific: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 Japan
        • 9.1.1.1.1 Overview
        • 9.1.1.1.2 Japan: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.1.3 Japan: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.1.4 Japan: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.1.4.1 Japan: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.1.4.2 Japan: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.1.5 Japan: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.2 China
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 China: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.3 China: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.2.4 China: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.2.4.1 China: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.2.4.2 China: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.2.5 China: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.3 India: Botulinum Toxin Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 India: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.3 India: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.3.4 India: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.3.4.1 India: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.3.4.2 India: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.3.5 India: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.4 South Korea
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 South Korea: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.3 South Korea: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.4.4 South Korea: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.4.4.1 South Korea: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.4.4.2 South Korea: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.4.5 South Korea: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.5 Australia
        • 9.1.1.5.1 Overview
        • 9.1.1.5.2 Australia: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.3 Australia: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.5.4 Australia: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.5.4.1 Australia: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.5.4.2 Australia: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.5.5 Australia: Botulinum Toxin Market Breakdown, by End User
      • 9.1.1.6 Rest of Asia Pacific
        • 9.1.1.6.1 Overview
        • 9.1.1.6.2 Rest of Asia Pacific: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.3 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Product
        • 9.1.1.6.4 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Application
        • 9.1.1.6.4.1 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Medical
        • 9.1.1.6.4.2 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Aesthetic
        • 9.1.1.6.5 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

  • 10.1 Merz Pharma GmbH & Co KGaA
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 AbbVie Inc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Ipsen SA
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Evolus Inc
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Medytox Inc
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Galderma SA
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Hugel Inc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Lanzhou Institute of Biological Products Co Ltd
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms